Why Cintas Corporation (CTAS) stock moved
Cintas Corporation (CTAS) shares rose 1.3% to $205.91 as of July 25, 2026, a modest gain from the prior close of $203.25. BestStocks flagged the session as a major change for CTAS. Below, we break down what changed for CTAS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CTAS climbed 1.3% to $205.91
CTAS rose 1.3% in its latest session, moving from $203.25 to $205.91.
What it means for Cintas Corporation investors
For Cintas Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 1.3% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $231.25, implying +12.3% upside from $205.91. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (39/100). With earnings roughly 60 days out, the next report is the most likely near-term test of the move.
CTAS price reaction
CTAS last traded at $205.91, up $2.66 (+1.31%) from the previous close of $203.25. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $169.08 and $206.25, and it currently sits about 99% of the way up that band.
Bullish and bearish analyst opinions on Cintas Corporation (CTAS)
The consensus analyst price target on Cintas Corporation (CTAS) is $231.25, 12.3% above the recent $205.91. Over the past 90 days analysts logged 1 upgrade, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CTAS line up.
The bullish case
- Wall Street's consensus price target of $231.25 implies +12.3% upside from $205.91.
- The Street's most bullish target is $250.00 (+21.4%).
- 1 analyst upgrade in the past 90 days, most recently B of A Securities to Buy (2026-07-16).
- Earnings beat with positive market reaction.
- Positive 1.3% session move.
The bearish case
- The bearish case is comparatively thin on recent signals; the main risk is that the climb toward the $231.25 consensus target has to be earned, and any of the risks BestStocks tracks could weigh on the shares.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 24, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CTAS
Frequently asked questions about CTAS
Why did Cintas Corporation (CTAS) stock move?
CTAS rose 1.3% to $205.91. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CTAS stock rise?
CTAS gained 1.31% ($2.66) versus the prior close of $203.25, last trading at $205.91 on 0.9× average volume.
When is Cintas Corporation's next earnings date?
CTAS's next earnings report is estimated for 2026-09-23 — about 60 days away.
What is the analyst price target for CTAS?
The consensus analyst price target for CTAS is $231.25, about 12.3% above the current $205.91. Over the past 90 days, analysts recorded 1 upgrade, 6 maintains, and 0 downgrades.
How BestStocks tracks CTAS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CTAS-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for CTAS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 25, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.